Nanotechnology increasingly plays a significant role in vaccine development. As vaccine
development orientates toward less immunogenic “minimalist” compositions, formulations …

We performed a quantitative review of 31 vaccine antibody response studies conducted from
1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly …

Over the last decade, there has been a flurry of research on adjuvants for vaccines, and
several novel adjuvants are now in licensed products or in late stage clinical development …

The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

Influenza continues to have a major worldwide impact, resulting in considerable human
suffering and economic burden. The regular recurrence of influenza epidemics is thought to …

The key objective of vaccination is the induction of an effective pathogen-specific immune
response that leads to protection against infection and/or disease caused by that pathogen …

With increasing age, the human immune system undergoes characteristic changes, termed
immunosenescence, which lead to increased incidence and severity of infectious diseases …

Age-related changes of the immune system contribute to increased incidence and severity of
infections in the elderly. Vaccination is the most effective measure to prevent infections and …

Vaccination represents the most effective form of protection against influenza infection.
While neutralizing antibodies are typically measured as a correlate of vaccine-induced …

Elderly people and subjects with underlying chronic diseases are at increased risk for
influenza and related complications. Conventional influenza vaccines provide only limited …